Featured Innovator

New TMC Innovation Institute director to focus on continued growth ahead of TMC3

Tom Luby will run the Texas Medical Center's Innovation Institute. Courtesy of TMC

Tom Luby is in his first week as TMC Innovation Institute director, but it's safe to say he's hit the ground running. The former head of JLABS @ TMC is ready to continue the growth of the institute as well as open up new doors to funding and the rest of the world.

"My hope is that I can be helpful to all the parties here to continue to recruit and grow great startups here," Luby says. "Critically important, too, is additional funding and bringing that here. And all of us are working together toward the successful launch of TMC3."

Luby spoke with InnovationMap about what all he has on his plate and how he plans on making Houston known for its life sciences.

InnovationMap: After working for Johnson & Johnson in Boston, when did you relocate Houston?

Tom Luby: In 2017, when the opportunity came up that I can join the team in Houston and grow our JLABS at TMC, I jumped at the chance, moved my family down to Houston, and have loved it ever since. I've loved the life science startup community here — it's small, but growing quickly — and what it has to offer to our family in terms of the diversity, the friendliness of people, the ease of getting to know people, and, obviously, the weather. When you come from the northeast, the Houston weather is nice.

IM: Boston has this major life science innovation reputation. How do we get Houston to have that same reputation?

TL: It's not very fair to compare Boston and Houston. The Boston life science community is around 40 years in the making. There's been a focus on that for a very long time, and as a result of all the startup activity through the '80s, '90s and into the 2000s, Boston has seen an influx of almost all the major pharmaceutical and biotech companies. All of them have footprints there because they want to be close to the startups. So, that mix of startup activity being embedded with lots of corporates has created a bit of a yin and yang situation — corporates are looking to pull the products from the startups into their pipelines and the startups have pulled talent from the corporates.

Houston's in a different place than that. If you roll the Boston tape back lets say 20 years where Boston was focused on generating a place where life science startups could have a chance to develop and be successful, that's where Houston is. We've gotten to a point where we're starting to see a really good density. Over the past four years, over 250 companies have touched down here at some point. That type of density is needed then to do that second part and recruit some of the larger health care corporations.

IM: Coming from J&J, what expertise do you feel like you are bringing to the table?

TL: What I hope to be helpful with is providing an overall strategic vision around TMC Innovation that allows us to scale from what's already been done here. Like I just mentioned, there have been 250 companies that have been here at some point in the past four years. That doesn't happen without the great efforts of those that came before me — the TMCx team in particular, but the JLABS team, the Biodesign team down the hall have created a really interesting and rapidly growing place for health care startups.

IM: What are some of your goals for the TMC Innovation Institute?

TL: In the short term, what we're going to focus on making sure that when people show up to the TMC Innovation Institute, they have a great experience, whether they are engaged with TMCx, biodesign, JLABS, etc. So, it's important for us to be well coordinated, working cooperatively together, and everyone focused on being service first when it comes to the startups here. What we hope to create is an environment where startups come and have an experience that leaves them knowing that that experience gives them the best chance at being successful. In addition, as we begin to engage with partners who can provide venture capital and angel funds, it's the same thing, that they come here and have an efficient, coordinated experience.

So short term, it's pulling it all together so that when you think of TMC Innovation, you know what it is, how it's organized and what our mission is. We'll also be making additional efforts to engage with the member institutions in TMC, and that they understand that we're a resource to them.

IM: The current TMCx cohort is the most international to date. Between that and the new focus on TMC's biobridges, why is a global presence so important to TMC Innovation?

TL: Biobridges are about making sure that important geographies outside the US understand that the TMC is a place where their startups can come and be successful.

It's important for TMC to use the bridge to gain insight and access into specific areas that we feel that those countries have core strengths in. Australia and its clinical trials networks is a great example of that. Our companies having access to tap into that is incredibly important. We know that those bio bridges will benefit our startups and give the startups there a chance to have access to us.

------

Portions of this interview have been edited.

Trending News

Building Houston

 
 

A Rice research team is tapping into materials science to better understand Alzheimer’s disease, a UH professor is developing a treatment for hereditary vision loss, and a BCM researcher is looking at stress and brain cancer. Photo by Gustavo Raskosky/Rice University

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, three Houston institutions are working on life-saving health care research thanks to new technologies.

Rice University scientists' groundbreaking alzheimer's study

Angel Martí (right) and his co-authors (from left) Utana Umezaki and Zhi Mei Sonia He have published their latest findings on Alzheimer’s disease. Photo by Gustavo Raskosky/Rice University

According to the Centers for Disease Control and Prevention, Alzheimer’s disease will affect nearly 14 million people in the U.S. by 2060. A group of scientists from Rice University are looking into a peptide associated with the disease, and their study was published in Chemical Science.

Angel Martí — a professor of chemistry, bioengineering, and materials science and nanoengineering and faculty director of the Rice Emerging Scholars Program — and his team have developed a new approach using time-resolved spectroscopy and computational chemistry, according to a news release from Rice. The scientists "found experimental evidence of an alternative binding site on amyloid-beta aggregates, opening the door to the development of new therapies for Alzheimer’s and other diseases associated with amyloid deposits."

Amyloid plaque deposits in the brain are a main feature of Alzheimer’s, per Rice.

“Amyloid-beta is a peptide that aggregates in the brains of people that suffer from Alzheimer’s disease, forming these supramolecular nanoscale fibers, or fibrils” says Martí in the release. “Once they grow sufficiently, these fibrils precipitate and form what we call amyloid plaques.

“Understanding how molecules in general bind to amyloid-beta is particularly important not only for developing drugs that will bind with better affinity to its aggregates, but also for figuring out who the other players are that contribute to cerebral tissue toxicity,” he adds.

The National Science Foundation and the family of the late Professor Donald DuPré, a Houston-born Rice alumnus and former professor of chemistry at the University of Louisville, supported the research, which is explained more thoroughly on Rice's website.

University of Houston professor granted $1.6M for gene therapy treatment for rare eye disease

Muna Naash, a professor at UH, is hoping her research can result in treatment for a rare genetic disease that causes vision loss. Photo via UH.edu

A University of Houston researcher is working on a way to restore sight to those suffering from a rare genetic eye disease.

Muna Naash, the John S. Dunn Endowed Professor of biomedical engineering at UH, is expanding a method of gene therapy to potentially treat vision loss in patients with Usher Syndrome Type 2A, or USH2A, a rare genetic disease.

Naash has received a $1.6 million grant from the National Eye Institute to support her work. Mutations of the USH2A gene can include hearing loss from birth and progressive loss of vision, according to a news release from UH. Naash's work is looking at applying gene therapy — the introduction of a normal gene into cells to correct genetic disorders — to treat this genetic disease. There is not currently another treatment for USH2A.

“Our goal is to advance our current intravitreal gene therapy platform consisting of DNA nanoparticles/hyaluronic acid nanospheres to deliver large genes in order to develop safe and effective therapies for visual loss in Usher Syndrome Type 2A,” says Naash. “Developing an effective treatment for USH2A has been challenging due to its large coding sequence (15.8 kb) that has precluded its delivery using standard approaches and the presence of multiple isoforms with functions that are not fully understood."

BCM researcher on the impact of stress

This Baylor researcher is looking at the relationship between stress and brain cancer thanks to a new grant. Photo via Andriy Onufriyenko/Getty Images

Stress can impact the human body in a number of ways — from high blood pressure to hair loss — but one Houston scientist is looking into what happens to bodies in the long term, from age-related neurodegeneration to cancer.

Dr. Steven Boeynaems is assistant professor of molecular and human genetics at Baylor College of Medicine. His lab is located at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and he also is a part of the Therapeutic Innovation Center, the Center for Alzheimer’s and Neurodegenerative Diseases, and the Dan L Duncan Comprehensive Cancer Center at Baylor.

Recently, the Cancer Prevention and Research Institute of Texas, or CPRIT, awarded Boeynaems a grant to continue his work studying how cells and organisms respond to stress.

“Any cell, in nature or in our bodies, during its existence, will have to deal with some conditions that deviate from its ideal environment,” Boeynaems says in a BCM press release. “The key issue that all cells face in such conditions is that they can no longer properly fold their proteins, and that leads to the abnormal clumping of proteins into aggregates. We have seen such aggregates occur in many species and under a variety of stress-related conditions, whether it is in a plant dealing with drought or in a human patient with aging-related Alzheimer’s disease."

Now, thanks to the CPRIT funding, he says his lab will now also venture into studying the role of cellular stress in brain cancer.

“A tumor is a very stressful environment for cells, and cancer cells need to continuously adapt to this stress to survive and/or metastasize,” he says in the release.

“Moreover, the same principles of toxic protein aggregation and protection through protein droplets seem to be at play here as well,” he continues. “We have studied protein droplets not only in humans but also in stress-tolerant organisms such as plants and bacteria for years now. We propose to build and leverage on that knowledge to come up with innovative new treatments for cancer patients.”

Trending News